Wednesday, 5th February 2014
Starts: 5 February 2014
Dr Weiguang Wang
Disulfiram - An anti-alcoholism medicine giving cancer patients new hope
Dr Wang obtained his MB in Hebei United University, China; Msc/MD in Beijing Postgraduate Medical School/PLA 301 Hospital, Beijing; PhD in Manchester Metropolitan University. Before joining University of Wolverhampton in 2005, he worked as a senior research scientist in Beatson Institute for Cancer Research, Glasgow.
- Targeting NF-κB pathway to improve cancer chemotherapy outcomes. Using microarray technology, Dr Wang identified NF-κB as a biological factor involved in cancer chemoresistance (Wang et al., Cancer Res 1998, 58:4426-33; 2004, 64:8167-76). Targeting NF-κB, using a clinically available antialcoholism drug, disulfiram (DSF), significantly enhances the cytotoxicity of conventional anticancer drugs to a wide range of cancer types and reverses chemoresistance in drug-resistant cancer cells. The anticancer mechanisms of DSF are investigated in his team. His group is aiming to identify NF-κB-targeting small molecules for anticancer drug development.
- Manipulation of NF-κB pathway to target cancer stem cells. Cancer contains a very small portion of cancer stem cells (CSCs) which are highly resistant to conventional anticancer drugs and become the source of post-chemotherapeutic cancer recurrence. In the recent years, Dr Wang’s team demonstrates that NF-κB pathway is one of the key regulators of CSCs. In collaboration with scientists in China, Spain and USA, they have developed nano-encapsulated long circulating DSF which shows anti-CSC activity in vitro and in vivo.
Redwood 2.60c (NLT)
1.30pm. Refreshments from 1:20pm
Open To: Public
Staff and Students